期刊
CANCER LETTERS
卷 315, 期 2, 页码 97-111出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2011.10.017
关键词
Antibody; Imaging; SPECT; Tumor; Optical
类别
资金
- US Department of Defense [BC074631, PC074289]
- National Institutes of Health [R21 CA156037, RO1 CA78590, UO1 CA111294, RO1 CA131944, RO1 CA133774, RO1 CA138791, RO3 CA 139285, P50 CA127297]
Antibodies, with their unmatched ability for selective binding to any target, are considered as potentially the most specific probes for imaging. Their clinical utility, however, has been limited chiefly due to their slow clearance from the circulation, longer retention in non-targeted tissues and the extensive optimization required for each antibody-tracer. The development of newer contrast agents, combined with improved conjugation strategies and novel engineered forms of antibodies (diabodies, minibodies, single chain variable fragments, and nanobodies), have triggered a new wave of antibody-based imaging approaches. Apart from their conventional use with nuclear imaging probes, antibodies and their modified forms are increasingly being employed with non-radioisotopic contrast agents (MRI and ultrasound) as well as newer imaging modalities, such as quantum dots, near infra red (NIR) probes, nanoshells and surface enhanced Raman spectroscopy (SERS). The review article discusses new developments in the usage of antibodies and their modified forms in conjunction with probes of various imaging modalities such as nuclear imaging, optical imaging, ultrasound, MRI, SEAS and nanoshells in preclinical and clinical studies on the diagnosis, prognosis and therapeutic responses of cancer. Published by Elsevier Ireland Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据